Cefixime: Difference between revisions

	WikiDoc Resources for Cefixime
Articles
Most recent articles on Cefixime Most cited articles on Cefixime Review articles on Cefixime Articles on Cefixime in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cefixime Images of Cefixime Photos of Cefixime Podcasts & MP3s on Cefixime Videos on Cefixime
Evidence Based Medicine
Cochrane Collaboration on Cefixime Bandolier on Cefixime TRIP on Cefixime
Clinical Trials
Ongoing Trials on Cefixime at Clinical Trials.gov Trial results on Cefixime Clinical Trials on Cefixime at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cefixime NICE Guidance on Cefixime NHS PRODIGY Guidance FDA on Cefixime CDC on Cefixime
Books
Books on Cefixime
News
Cefixime in the news Be alerted to news on Cefixime News trends on Cefixime
Commentary
Blogs on Cefixime
Definitions
Definitions of Cefixime
Patient Resources / Community
Patient resources on Cefixime Discussion groups on Cefixime Patient Handouts on Cefixime Directions to Hospitals Treating Cefixime Risk calculators and risk factors for Cefixime
Healthcare Provider Resources
Symptoms of Cefixime Causes & Risk Factors for Cefixime Diagnostic studies for Cefixime Treatment of Cefixime
Continuing Medical Education (CME)
CME Programs on Cefixime
International
Cefixime en Espanol Cefixime en Francais
Business
Cefixime in the Marketplace Patents on Cefixime
Experimental / Informatics
List of terms related to Cefixime

Cefixime
	File:Cefixime.png
Clinical data
Pregnancy; category	B;
Routes of; administration	Oral
ATC code	J01DD08 (WHO) ;
Pharmacokinetic data
Bioavailability	40% to 50%
Protein binding	Approximately 60%
Elimination half-life	Variable; Average 3 to 4 hours
Excretion	Renal and biliary
Identifiers
	IUPAC name (6R,7R)-7-{[2-(2-amino-1,3-thiazol-4-yl)-2-(carboxy; methoxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia-; 1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;
CAS Number	79350-37-1;
PubChem CID	54362;
DrugBank	APRD00583;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C16H15N5O7S2
Molar mass	453.452 g/mol

VisualWikitext

Revision as of 14:50, 2 January 2014

Cefixime is an oral third generation cephalosporin antibiotic. It was sold under the trade name Suprax in the USA, until 2003 when it was taken off the market by drug manufacturer Wyeth after its patent expired. the oral suspension form of "Suprax" was re-launched by Lupin in the USA. Cefixime is still available in Canada. It is used to treat gonorrhea^[1], tonsilitis^[2], and pharyngitis^[2].

References

↑ McMillan A, Young H. (2007). "The treatment of pharyngeal gonorrhoea with a single oral dose of cefixime". Int J STD AIDS. 18 (4): 253–4. PMID 17509176.
↑ ^2.0 ^2.1 Adam D, Hostalek U, Tröster K. (1995). "5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: comparison with 10-day penicillin V therapy". Infection. 23 (Suppl 2): S83–6. PMID 8537138.

External links

Suprax Online - Information about cefixime.
Notice to Readers: Discontinuation of Cefixime Tablets --- United States - A FDA report alerting physicians about the discontinuation of cefixime.

th:เซฟิกซิม

Template:WS

[McMillan-2007-1] McMillan A, Young H. (2007). "The treatment of pharyngeal gonorrhoea with a single oral dose of cefixime". Int J STD AIDS. 18 (4): 253–4. PMID 17509176.

[Adam-1995-2] 2.0 ^2.1 Adam D, Hostalek U, Tröster K. (1995). "5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: comparison with 10-day penicillin V therapy". Infection. 23 (Suppl 2): S83–6. PMID 8537138.

[1]

[2]

v t e Antibacterials: cell wall disruption (J01C-J01D)
Internal to membrane/ (inhibit peptidoglycan subunit synthesis and transport)	Template:Navbox subgroup
Glycopeptide/ (inhibit PG chain elongation)	Vancomycin # (Oritavancin, Telavancin) · Teicoplanin (Dalbavancin) · Ramoplanin
Beta-lactams/ (inhibit cross-links with PBP)	Template:Navbox subgroup
Other	Template:Navbox subgroup
# = WHO-EM

Revision as of 15:23, 4 September 2012 (view source) WikiBot (talk \| contribs) m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist\|2}}, -{{reflist}} +{{reflist\|2}})) ← Older edit	Revision as of 14:50, 2 January 2014 (view source) Gerald Chi (talk \| contribs) m (Changed protection level for "Cefixime" ([Edit=Allow only autoconfirmed users] (expires 14:50, 16 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 14:50, 16 January 2014 (UTC)))) Newer edit →
(No difference)

Clinical data
File:Cefixime.png
Pregnancy category	B
Routes of administration	Oral
ATC code	J01DD08 (WHO)
Pharmacokinetic data
Bioavailability	40% to 50%
Protein binding	Approximately 60%
Elimination half-life	Variable Average 3 to 4 hours
Excretion	Renal and biliary
Identifiers
IUPAC name (6R,7R)-7-{[2-(2-amino-1,3-thiazol-4-yl)-2-(carboxy methoxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia- 1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CAS Number	79350-37-1
PubChem CID	54362
DrugBank	APRD00583
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₆H₁₅N₅O₇S₂
Molar mass	453.452 g/mol

Cefixime: Difference between revisions

Revision as of 14:50, 2 January 2014

References

External links

Navigation menu